JETREA(R) is the first and only pharmacological drug approved by the
JETREA(R) was approved in the
JETREA(R) contains the active substance ocriplasmin. It is administered through a single intravitreal injection to treat adults with symptomatic VMA.
Symptomatic VMA is a progressive, sight-threatening condition. It is caused by the vitreous humour having an abnormally strong attachment to the macula, the central part of the retina (the light sensitive membrane at the back of the eye). The macula provides central vision that is needed for everyday tasks such as driving, reading and recognizing faces.
When the vitreous humour shrinks, the strong attachment results in a pulling force on the retina, which may lead to visual distortion, decreased visual acuity and central blindness.
JETREA(R) breaks down the protein fibers which cause the abnormal traction between the vitreous and the macula that cause symptomatic VMA. By dissolving these proteins, JETREA(R) releases the traction, and helps to complete the detachment of the vitreous from the macula.
Most Popular Stories
- Updates on Everglades' Stranded Pilot Whales
- NSA Tracks 5 Billion Cellphone Records a Day
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Stolen Cobalt-60 Recovered in Mexico
- Ford Mustang Still Packs Power
- Wind Power and Wildlife Can Coexist
- Allstate Seeks to Invest in Minority Firms
- Sarmiento to Handle Greeley Latin Ops
- First-time Jobless Claims Drop Below 300,000
- White House Pushes to Extend Unemployment Benefits